Laupheim, Germany, June 6, 2014 / B3C newswire / – Rentschler Biotechnologie GmbH, a leading contract manufacturing organization (CMO) for the development and production of biopharmaceuticals, announce the addition of a 2,000 L single-use bioreactor to its facility in Laupheim. The expansion is anticipated to be fully operational end of the first quarter of 2015.
The new 2,000 L single-use bioreactor will supplement two existing 1,000 L single-use bioreactors already in operation and will double the total single-use production capacity.
“We see an increasing need for production capacity in the mid-scale. The expansion will allow us to match the growing demands of our clients for all clinical phases. The addition of the 2,000 L single-use bioreactor will increase our flexibility to serve the market with either stainless steel or single-use technology as the client requires”, explains Frank Ternes, Chief Business Officer at Rentschler.
In 2012, Rentschler received the “Facility of the Year Award” for its flexible, multi-product 1,000 L manufacturing facility designed to minimize manufacturing costs and product cycle times. Single-use equipment reduces contamination risks and permits a faster product turnaround with a shortened setup time and hence increases the capacity utilization. The facility features a flexible space concept comprising four independent, connectable, multi-purpose clean room suites. The new 2,000 L single-use bioreactor seamlessly integrates in this proven facility concept.
Rentschler is one of the first CMOs having established a fully disposable process concept and already has more than three years of experience with this system.
Rentschler is a CMO with over 35 years proven track record in biopharmaceuticals. Focused on the utilization of mammalian cell lines, Rentschler’s long experience covers the development and production of recombinant proteins in compliance with international GMP standards. Rentschler’s customized solutions range from supporting drug candidate selection, cell line and process development capabilities as well as GMP production to comprehensive analytics and fill & finish. Rentschler’s state-of-the-art manufacturing facility includes bioreactors up to 3,000 L and aseptic filling lines for vials (including lyophilization) and prefilled syringes. The long-term experience with international regulatory affairs and authorities complements the offerings. Rentschler’s full-service concept allows flexibility on the individual project requirements.
Dr. Marion Schrader
Senior Director Marketing
Rentschler Biotechnologie GmbH
Tel.: +49 (0) 7392 701 491